Day: October 23, 2020

98416-72-9,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.98416-72-9,6-Bromo-2-chloro-3-methylquinoxaline,as a common compound, the synthetic route is as follows.

General procedure: Method B: 4-[(4-substituted phenylimino)methyl]phenol(0.01 mol) was dissolved in acetonitrile (50 mL). Anhydrous potassiumcarbonate (2.0 g) was added to the mixture, which wasrefluxed for 1 h, then (5, 0.01 mol) was added and the mixturewas further refluxed for 8 h (monitored by TLC). After completionof the reaction, the mixture was filtered and the excess of acetonitrilewas evaporated under reduced pressure to produce the correspondingcompounds

The synthetic route of 98416-72-9 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Abbas, Hebat-Allah S.; Al-Marhabi, Aisha R.; Eissa, Sally I.; Ammar, Yousry A.; Bioorganic and Medicinal Chemistry; vol. 23; 20; (2015); p. 6560 – 6572;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

1210048-05-7, 7-Bromo-5-fluoroquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

EXAMPLE 365-Fluoro-7-[3-(piperidin-l-ylmethyl)phenyllquinoxalineGlyoxal (10 drops of a 40% solution in water) was added to a solution of 5- bromo-2,3-diaminofluorobenzene (82 mg, 0.4 mmol) in ethanol (3 mL). The mixture was stirred and left to stand at r.t. for 1 h. The mixture was partitioned between water and EtOAc (20 mL each), and the organic phase was dried (MgSO4) and concentrated in vacuo. The residue was dissolved in DME (1.2 mL), and 3-(piperidin-l-ylmethyl)phenyl- boronic acid pinacol ester hydrochloride (135 mg, 0.4 mmol), 2M aqueous sodium carbonate solution (0.6 mL, 0.9 mmol) and Pd(PPh3)4 (14 mg, 0.012 mmol) were added. The mixture was heated to 12O0C in a sealed tube, under microwave irradiation, for 20 minutes. The mixture was partitioned between water and EtOAc (2 mL each), and the organic phase was concentrated in vacuo. The residue was purified by preparative HPLC to give the title compound (23 mg, 18% over the two steps) as a pale yellow-brown gum. deltaH (CDCl3) 8.94 (d, IH), 8.89 (d, IH), 8.17 (s, IH), 7.80 (d, IH), 7.72 (s, IH), 7.64 (d, IH), 7.48 (t, IH), 7.43 (d, IH), 3.64 (s, 2H), 2.40-2.60 (m, 4H), 1.55-1.70 (m, 4H), 1.39- 1.54 (m, 2H). LCMS (ES+) 322 (M+H)+, RT 2.25 minutes., 1210048-05-7

As the paragraph descriping shows that 1210048-05-7 is playing an increasingly important role.

Reference£º
Patent; UCB PHARMA S.A.; BUeRLI, Roland; HAUGHAN, Alan, Findlay; MACK, Stephen, Robert; PERRY, Benjamin, Garfield; RAPHY, Gilles; SAVILLE-STONES, Elizabeth, Anne; WO2010/52448; (2010); A2;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

53967-21-8, 6-(Bromomethyl)quinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

2-(4-tert-butylphenyl)-4-{[4-(6-quinoxalyl)methyl]piperazin-1-yl}benzimidazole; To a suspension of 2-(4-t-butylphenyl)-4-piperazin-1-yl-1H-benzimidazole (49.5 g, 0.148 mol) and potassium carbonate (40.0 g, 0.29 mol) in acetone (0.800 L, EM) was added 6-bromomethylquinoxaline (33.0 g, 0.148 mol) as a solid in one portion at room temperature. The reaction mixture was stirred for 22 h at ambient temperature. The product precipitated out of solution was separated by filtration; the cake was washed with 30 mL of acetone, then triturated with 0.8 L of water and filtered again. The trituration procedure was repeated two more times. The resulting solid was dried in a stream of air first, then in a vacuum desiccator over CaSO4 to give 70 g (0.147 mol) of the desired product as a white amorphous solid. Purity 98% (HPLC at 254 nm)., 53967-21-8

As the paragraph descriping shows that 53967-21-8 is playing an increasingly important role.

Reference£º
Patent; Wyeth; US2005/282820; (2005); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

1204-75-7, 3-Oxo-3,4-dihydroquinoxaline-2-carboxylic acid is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

H2SO4 (16 mL) was added dropwise to a stirred solution of 3-hydroxy-2-quinoxalinecarboxylic acid (9.3 g, 49.0 mmol) in methanol (245 mL) at room temperature. After the mixture was stirred at room temperature overnight, the methanol was removed under vacuum. The residue thus obtained was dissolved in ethyl acetate and washed with water. The organic layer was separated, washed with brine, dried over anhydrous MgSO4, and concentrated in vacuo to afford 8.03 g of crude methyl 3-hydroxyquinoxaline-2-carboxylate as a light orange solid. LC-MS (M+H): 205.0., 1204-75-7

1204-75-7 3-Oxo-3,4-dihydroquinoxaline-2-carboxylic acid 71001, aquinoxaline compound, is more and more widely used in various fields.

Reference£º
Patent; TaiGen Biotechnology Co., Ltd.; US2008/292626; (2008); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

32601-86-8, 2-Chloro-3-methylquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a mixture of 2-chloro-3-methylquinoxaline (89 mg, 0.50 mmol, 1 equiv), N-Boc-2- pyrroleboronic acid (158 mg, 0.75 mmol, 1.5 equiv), and K3P045H20 (0.45 g, 1.5 mmol, 3 equiv) was added THF (400 iL) then a THF stock solution of 3 and PAd3 (100 .iL, 0.25 imol of Pd/PAd3). The mixture was stirred at 70 C for 5 h. The reaction mixture was diluted with ethylacetate then extracted with water. The combine organic layers were evaporated and the crude product was purified by flash chromatography. After drying, 148 mg (96 %) of 30 was obtained as a white solid.1H NMR (501 MHz, CDC13) 8.09 – 7.98 (m, 2H), 7.74 – 7.63 (m, 2H), 7.43 (dd, J 3.4, 1.7 Hz, 1H), 6.44 (dd, J= 3.3, 1.7 Hz, 1H), 6.33 (t, J= 3.4 Hz, 1H), 2.56 (s, 3H), 1.17 (s, 9H).3C{1H} NMR (126 MHz, CDC13) oe 154.5, 149.6, 148.6, 141.2, 140.3, 130.7, 129.8, 129.1,129.0, 128.3, 122.5, 115.6, 111.4, 84.2, 27.4, 23.0.HRIVIS (ESI) mlz calculated for C18H19N302 (M+1) 310.1550, found 310.1552., 32601-86-8

32601-86-8 2-Chloro-3-methylquinoxaline 236276, aquinoxaline compound, is more and more widely used in various fields.

Reference£º
Patent; THE TRUSTEES OF PRINCETON UNIVERSITY; CARROW, Brad P.; CHEN, Liye; (51 pag.)WO2017/75581; (2017); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

83570-42-7, 1-(Quinoxalin-6-yl)ethanone is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Titanium tetraisopropoxide (0.1 mL, 0.34 mmol) was added to a stirred suspension of Intermediate 3a (71 mg, 0.31 mmol) and l-(quinoxalin-6-yl)ethanone (CAS: 83570-42- 7; 63 mg, 0.37 mmol) in THF (1.5 mL) at rt and under N2 atmosphere. The mixture was stirred into a sealed tube at 80 C for 16 h. Then sodium cyanoborohydride (30 mg, 0.48 mmol) was added and the mixture was further stirred at 80 C for 16 h. Then, NaHC03 (aq. sat. soltn.) and DCM were added to the mixture. The solvent was evaporated in vacuo and the crude product was purified by flash column (0320) chromatography (silica gel, 7N solution of NH3 in MeOH in DCM, from 0/100 to 10/90) and then by RP HPLC (Stationary phase: CI 8 XBridge 30 x 100 mm 5 muetaiota; mobile phase: gradient from 81% lOmM NH4CO3H pH 9 solution in water, 19% CH3CN to 64% lOmM NH4CO3H pH 9 solution in water, 36% CH3CN). The desired fractions were collected and concentrated in vacuo to yield product 6 (15 mg, 13% yield) as yellow oil., 83570-42-7

83570-42-7 1-(Quinoxalin-6-yl)ethanone 22631249, aquinoxaline compound, is more and more widely used in various fields.

Reference£º
Patent; JANSSEN PHARMACEUTICA NV; BARTOLOME-NEBREDA, Jose Manuel; TRABANCO-SUAREZ, Andres Avelino; MARTINEZ VITURRO, Carlos Manuel; (116 pag.)WO2018/141984; (2018); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

1593-08-4, 2-Formylquinoxaline is a quinoxaline compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: A 25 mL pressure vial was charged with 2-methylquinoline (1a) (71.5 mg, 0.50 mmol, 1.0 equiv.), I2 (317.3 mg, 1.25 mmol, 2.5 equiv.) and DMSO (3.0 mL). The vial was sealed and the resulting mixture was stirred at 110 C for 4-6 h under an air atmosphere, after disappearance of the reactant (monitored by TLC), then added benzohydrazide (2a) (81.6 mg, 0.6 mmol, 1.2 equiv.) , K2CO3 (414.0 mg, 3.0 mmol, 6.0 equiv.) at 110 C for another 4-6 h. After the reaction completed, and added 50 mL water to the mixture, then extracted with EtOAc 3 times (3 ¡Á 50 mL). The extract was washed with 10% Na2S2O3 solution (w/w), dried over anhydrous Na2SO4 and concentrated under reduced pressure. The residue was puried by flash column chromatography on silica gel to yield the corresponding product 3aa as a yellow solid (72% yield).

1593-08-4, As the paragraph descriping shows that 1593-08-4 is playing an increasingly important role.

Reference£º
Article; Shang, Zhi-Hao; Sun, Ji-Na; Guo, Jiang-Shan; Sun, Yuan-Yuan; Weng, Wei-Zhao; Zhang, Zhen-Xiao; Li, Zeng-Jing; Zhu, Yan-Ping; Tetrahedron; vol. 76; 6; (2020);,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.6925-00-4,Quinoxaline-6-carboxylic acid,as a common compound, the synthetic route is as follows.

6925-00-4, To a solution of quinoxaline-6-carboxylic acid (438 mg, 2.51 mmol) in benzene (16 mL) was added oxalyl chloride (0.26 mL, 3.02 mmol) and anhydrous DMF (0.1 mL). The reaction was stirred at room temperature for 30 minutes after which the mixture was concentrated in vacuo. The resulting yellow solid was azeotroped 3x with toluene and the product was used immediately without further purification

As the paragraph descriping shows that 6925-00-4 is playing an increasingly important role.

Reference£º
Patent; MERCK & CO., INC.; WO2006/14618; (2006); A2;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

6925-00-4,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.6925-00-4,Quinoxaline-6-carboxylic acid,as a common compound, the synthetic route is as follows.

Method 3; tert-Butyl {4-methyl-3-r(quinoxalin-6-ylcarbonyl’)amino1phenyl>carbamate; A solution of tert-butyl (3-amino-4-methylphenyl)carbamate (Method 2; 50.10 g, 0.23 mol), quinoxaline-6-carboxylic acid (50.10 g, 0.23 mol) and diisoproplyethylamine (70 ml, 0.68 mol) in DMF (575 ml) was treated with HATU (94.3 g, 0.25 mol). The reaction was stirred at 25 0C for 24 h. The reaction was quenched with H2O and extracted with EtOAc. The organics were dried with NaCl (sat) and then Na2SO4 (s) and removed under reduced pressure. The resulting solid was recrystallized from DCM/hexanes affording the product as brown crystals; m/z 379.

As the paragraph descriping shows that 6925-00-4 is playing an increasingly important role.

Reference£º
Patent; ASTRAZENECA AB; ASTRAZENECA UK LIMITED; WO2006/40568; (2006); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.108258-54-4,Methyl 2,3-dichloroquinoxaline-6-carboxylate,as a common compound, the synthetic route is as follows.

Step C hydrazine monohydrate (0.26 ML) was added dropwise to a suspension of 2,3-dichloro-quinoxaline-6-carboxylic acid methyl ester (1.2 g) in methanol (10 ML) at -10 C. After three hrs. at this temperature, an additional portion of hydrazine monohydrate (0.26 ML) was added, and the resulting mixture was stirred at 0 C. for three hrs., and then for one hr. at 23 C. The suspension was filtered, and the solids were washed with MeOH. Flash column chromatography provided a residue that was recrystallized from MeOH to provide 3-chloro-2-hydrazino-quinoxaline-6-carboxylic acid methyl ester as a yellow solid. MS (M+H)+=253.2.

108258-54-4, The synthetic route of 108258-54-4 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Pfizer Inc.; US2004/192698; (2004); A1;,
Quinoxaline – Wikipedia
Quinoxaline | C8H6N2 | ChemSpider